TABLE 1.
Summary characteristics of studies included in the meta-analysis
| Author, yr | No. of patients with CD, no. of controls | Median or mean (range or 95% CI) age (yr) of patients with CD, controls | No. of female/no. of male patients with CD, controls | tTG type | Manufacturer or assay | Cutoff value | Se (%) | Sp (%) |
|---|---|---|---|---|---|---|---|---|
| Sugai, 2000 | 79, 42 (18 diseased) | 37 (17-68), 35 (18-66) | 61/18 | gp | INOVA | 20 AU/ml | 92 | 98 |
| 39/21 | ||||||||
| Martini, 2002 | 101, 190 (101 diseased) | 37 (21-72), 38 (20-77) | 61/81 | rh | Pantec | 12.8 AU/ml | 83 | 92 |
| 39/21 | rh | Eurospital | 7.4 AU/ml | 96 | 82 | |||
| rh | Li StarFISH | 19.7 AU/ml | 66 | 91 | ||||
| rh | Pharmacia | 2 AU/ml | 80 | 99 | ||||
| gp | Genesis | 47.5 AU/ml | 76 | 93 | ||||
| Burgin-Wolf, 2002 | 208, 157 diseased | 6.7, 10.1 | 144/64 | rh | Pharmacia | 6 U/ml | 96 | 99 |
| 87/70 | ||||||||
| Basso, 2001 | 38, 34 diseased | (2-16), (1-14) | 28/10 | rh | Eurospital | 5.5 AU | 89 | 100 |
| 19/15 | gp | Medipan | 26 U/ml | 84 | 100 | |||
| ph | INOVA | 20 U | 84 | 100 | ||||
| Arnika | 0 U/ml | 76 | 100 | |||||
| Tesei, 2003 | 250 (203 type IV VAa), 176 diseased | 39 (13-79), 40 (17-83) | 184/66 | rh | Eurospital | 7 AU/ml | 93 | 95 |
| 132/44 | ||||||||
| Carroccio, 2002 | 24 (17 total VA), 183 diseased | 30 (18-80), 46 (17-84) | 14/10 | rh | Eurospital | 100 | 97 | |
| 94/89 | gp | Eurospital | 100 | 92 | ||||
| Wong, 2002 | 49, 34 diseased | >2, >2 | rh | Aesku Lab | 15 U/ml | 71 | 100 | |
| rh | Binding site | 4 U/ml | 98 | 91 | ||||
| rh | Eurospital | 7 AU | 96 | 88 | ||||
| ph | INOVA | 20 U/ml | 98 | 100 | ||||
| ph | Orgentec | 10 U/ml | 100 | 85 | ||||
| rh | Varelisa | 5 U/ml | 100 | 100 | ||||
| gp | Binding site | 4 U/ml | 88 | 91 | ||||
| gp | Eurospital | 5 AU | 98 | 35 | ||||
| gp | Genesis | 10 U/ml | 96 | 77 | ||||
| gp | Immco Diagn. | 20 EU/ml | 92 | 77 | ||||
| gp | Im/pharcology | 25 AU | 100 | 12 | ||||
| gp | INOVA | 20 U/ml | 86 | 100 | ||||
| gp | Medipan | 25 U/ml | 98 | 53 | ||||
| Hansson, 2000 | 22 (11 total VA), 45 (23 diseased) | 3 (1-16), 6 (1-16) | 14/8 | ph | Homemade | 0.06 AU | 100 | 98 |
| 9/13 | gp | Sigma | 0.06 AU | 91 | 98 | |||
| Sblattero, 2000 | 65 (18 total VA), 170 (20 diseased) | (2-60), (18-60) | 34/31 | rh | Homemade | 91 | 99 | |
| 75/95 | gp | Homemade | 82 | 98 | ||||
| Hansson, 2002 | 25, 53 (29 diseased) | 4 (1-16), 5 (1-18) | 27/26 | rh | Pharmacia | 4.7 AU/ml | 100 | 96 |
| Trevisiol, 2002 | 140 (111 stage type 3c-b), 200 healthy | (1-60), 7 (2-14) | 93/47 | rh | Homemade | 100 | 100 | |
| 105/95 | ||||||||
| Blackwell, 2002 | 32, 38 diseased | rh | Binding site | Those provided by the manufacturers | 100 | 84 | ||
| rh | Pharmacia | 91 | 97 | |||||
| ph | INOVA | 88 | 87 | |||||
| ph | Euroimmun | 94 | 92 | |||||
| gp | Binding site | 50 | 38 | |||||
| Johnston, 2003 | 29, 63 diseased | 52.5, 51.8 | 15/14 | gp | Immco Diagn. | 25 U | 86 | 84 |
| 44/19 | ||||||||
| Fabiani, 2001 | 399, 432 (186 diseased) | 13.5 (0.3-87.4), 13.2 (0.4-78.7) | 256/143 | gp | Eurospital | 7 AU | 90 | 96 |
| 212/220 | ||||||||
| Vitoria, 1999 | 27, 34 diseased | 5.02 ± 4.7, 5.9 ± 4.8 | gp | Medipan | 35 U/ml | 100 | 94 | |
| Scoglio, 2003 | 134 (134 subtotal VA), 47 diseased | <18 yrs (100 subjects) <18 yrs (81 subjects) | gp | Homemade | 99 | 66 | ||
| Llorente, 2004 | 61, 64 diseased | Pharmacia | 3.5 AU/ml | 100 | 95 | |||
| Wolters, 2002 | 52, 49 diseased | 4 (1.1, 14.4), 5.1 (0.8, 19.2) | 38/14 | rh | Pharmacia | 99 | 99 | |
| 20/29 | gp | Homemade | 95 | 92 | ||||
| Leon, 2001 | 86, 152 diseased | rh | Pharmacia | 99 | 99 | |||
| gp | Homemade | 95 | 92 | |||||
| Osman, 2002 | 35, 137 (48 diseased) | (2-81), (2-81) | ph | Homemade | 19 U | 100 | 98.6 | |
| gp | Homemade | 85.7 | 99.3 | |||||
| Kumar, 2001 | 34, 267 (161 diseased) | gp | Homemade | 91 | 97 |
a
VA, villous atrophy.